No evidence for functional selectivity of proxyfan at the human histamine H3 receptor coupled to defined Gi/Go protein heterotrimers

Journal of Pharmacology and Experimental Therapeutics

Volumn 332, Issue 3, 2010, Pages 996-1005

  Schnell, David ^a   Burleigh, Katrina ^a   Trick, Jonathan ^a,c   Seifert, Roland ^b  

^a UNIVERSITY OF REGENSBURG   (Germany)

^b HANNOVER MEDICAL SCHOOL   (Germany)

^c UNIVERSITY OF TORONTO   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA METHYLHISTAMINE; CIPROXYFAN; CLOBENPROPIT; HETEROTRIMERIC GUANINE NUCLEOTIDE BINDING PROTEIN; HISTAMINE; HISTAMINE H3 RECEPTOR; HYBRID PROTEIN; IMETIT; IMIDAZOLE DERIVATIVE; IMPENTAMINE; N METHYLHISTAMINE; PROXYFAN; THIOPERAMIDE; UNCLASSIFIED DRUG;

ARTICLE; BACULOVIRUS EXPRESSION SYSTEM; DRUG SELECTIVITY; DRUG STRUCTURE; DRUG TARGETING; INSECT CELL CULTURE; LIGAND BINDING; POLYACRYLAMIDE GEL ELECTROPHORESIS; PRIORITY JOURNAL; PROTEIN CONFORMATION; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; STEADY STATE; STOICHIOMETRY;

ANIMALS; CELL LINE; GTP-BINDING PROTEIN ALPHA SUBUNIT, GI2; GTP-BINDING PROTEIN ALPHA SUBUNITS, GI-GO; HISTAMINE AGONISTS; HISTAMINE ANTAGONISTS; HUMANS; IMIDAZOLES; LIGANDS; PROTEIN MULTIMERIZATION; RECEPTORS, HISTAMINE H3; RECOMBINANT FUSION PROTEINS;

EID: 77249176747     PISSN: 00223565     EISSN: 15210103     Source Type: Journal    
DOI: 10.1124/jpet.109.162339     Document Type: Article

References (40)

1. Birnbaumer L (2007) Expansion of signal transduction by G proteins. The second 15 years or so: from 3 to 16 α subunits plus βγ dimers. Biochim Biophys Acta 1768:772-793.
2. Bonaventure P, Letavic M, Dugovic C, Wilson S, Aluisio L, Pudiak C, Lord B, Mazur C, Kamme F, Nishino S, et al. (2007) Histamine H3 receptor antagonists: from target identification to drug leads. Biochem Pharmacol 73:1084-1096.
3. Bongers G, Bakker RA, and Leurs R (2007) Molecular aspects of the histamine H3 receptor. Biochem Pharmacol 73:1195-1204.
4. 35S]GTPγS binding to pertussis toxin. Eur J Pharmacol 296:223-225.
5. i-coupled receptors. Anal Biochem 270:242-248.
6. 3 antagonists. Mini Rev Med Chem 4:979-992.
7. Drutel G, Peitsaro N, Karlstedt K, Wieland K, Smit MJ, Timmerman H, Panula P, and Leurs R (2001) Identification of rat H3 receptor isoforms with different brain expression and signaling properties. Mol Pharmacol 59:1-8.
8. Esbenshade TA, Browman KE, Bitner RS, Strakhova M, Cowart MD, and Brioni JD (2008) The histamine H3 receptor: an attractive target for the treatment of cognitive disorders. Br J Pharmacol 154:1166-1181.
9. o G proteins: evidence for agonist regulation of G protein selectivity. Br J Pharmacol 138:775-786.
10. 3 receptors in vitro and in vivo. Proc Natl Acad Sci U S A 100:11086-11091.
11. sα proteins in Sf9 insect cells: limitations in comparison with fusion proteins. Biochim Biophys Acta 1613:101-114.
12. s proteins. J Biol Chem 277:34434-34442.
13. Haas HL, Sergeeva OA, and Selbach O (2008) Histamine in the nervous system. Physiol Rev 88:1183-1241.
14. 3-receptor antagonists with benzyl ether structure or related moieties: synthesis and structure-activity relationships. Arch Pharm (Weinheim) 329:379-385.
15. Kenakin T (1997) Differences between natural and recombinant G protein-coupled receptor systems with varying receptor/G protein stoichiometry. Trends Pharmacol Sci 18:456-464.
16. Kenakin T (2001) Inverse, protean, and ligand-selective agonism: matters of receptor conformation. FASEB J 15:598-611.
17. Kenakin T (2007) Functional selectivity through protean and biased agonism: who steers the ship? Mol Pharmacol 72:1393-1401.
18. o-proteins in Sf9 insect cells. Naunyn Schmiedebergs Arch Pharmacol 378:261-274.
19. Kobilka BK and Deupi X (2007) Conformational complexity of G-protein-coupled receptors. Trends Pharmacol Sci 28:397-406.
20. 3 receptor ligands: evidence for heterogeneous active state receptor conformations. J Pharmacol Exp Ther 314:271-281.
21. 3 receptor drugs. Nat Rev Drug Discov 4:107-120.
22. 3 receptor reveals distinct species pharmacological profiles. J Pharmacol Exp Ther 293:771-778.
23. 2. Neurosci Lett 447:68-72.
24. Ostrom RS and Insel PA (2004) The evolving role of lipid rafts and caveolae in G protein-coupled receptor signalling: implications for molecular pharmacology. Br J Pharmacol 143:235-245.
25. 2 receptors. J Pharmacol Exp Ther 321:983-995.
26. 4-receptor. Biochemistry 48:1424-1438.
27. sα splice variants. J Pharmacol Exp Ther 298:840-847.
28. Seifert R and Dove S (2009) Functional selectivity of GPCR ligand stereoisomers: new pharmacological opportunities. Mol Pharmacol 75:13-18.
29. s interactions: evidence for multiple receptor conformations. Mol Pharmacol 56:348-358.
30. Seifert R and Wenzel-Seifert K (2002) Constitutive activity of G-protein-coupled receptors: cause of disease and common property of wild-type receptors. Naunyn Schmiedebergs Arch Pharmacol 366:381-416.
31. Seifert R, Wenzel-Seifert K, and Kobilka BK (1999b) GPCR-Gα fusion proteins: molecular analysis of receptor-G-protein coupling. Trends Pharmacol Sci 20:383-389.
32. sα has properties of a constitutively active receptor. J Biol Chem 273:5109-5116.
33. 32P]GMP. Biochim Biophys Acta 562: 11-31.
34. 2-adrenoceptors with isoproterenol, epinephrine, norepinephrine, and dopamine. J Pharmacol Exp Ther 327:760-769.
35. q-proteins. Mol Pharmacol 58:954-966.
36. 3. J Biol Chem 274:33259-33266.
37. Wenzel-Seifert K, Hurt CM, and Seifert R (1998) High constitutive activity of the human formyl peptide receptor. J Biol Chem 273:24181-24189.
38. 1-receptor. Mol Pharmacol 76:25-37.
39. 2-adrenoceptor to different G proteins in cardiomyocytes. Mol Pharmacol 75:158-165.
40. 3 receptor heterogeneity. Neuropharmacology 44:773-786.